Specifications TableTableSubject area*Chemistry, Biology, Cancer immunology*More specific subject area*Structural biology*Type of data*Parameter table for structurally observed water molecules; figures depicting positions of these waters in a binding interface*How data was acquired*Analysis of the refined X-ray crystallographic structure.*Data format*Table, figures.*Experimental factors*Fab fragments from anti-CD269 (BCMA) IgGs co-crystallized with antigen and the structure solved to high (1.89 Å) resolution*Experimental features*Interface interactions in the refined structure were assessed and the contribution of water to the binding evaluated.*Data source location*Protein Data Bank*Data accessibility[〈http://www.rcsb.org/pdb/home/home.do](http://www.rcsb.org/pdb/home/home.do){#ir0005}[〉](http://www.rcsb.org/pdb/home/home.do){#ir0010} (*PDB code:* 4*ZFO*)

Value of the data {#s0005}
=================

•The antibody targets the very restrictively expressed tumor marker BCMA for Multiple Myeloma and potently inhibits tumor growth in mice•The antibody has an exceptionally high affinity to BCMA (picomolar)•The high resolution crystal structure of the antibody-BCMA complex reveals a network of water molecules in the binding interface•The structure shows how very high affinity can be achieved with a minimal number of direct protein-protein contacts

1. Data, experimental design, materials and methods {#s0010}
===================================================

Multiple Myeloma (MM) is an incurable malignancy of antibody-secreting B cells (plasma cells) with a mean life expectancy of 5 years from diagnosis [@bib1]. We generated a chimeric mouse/human antibody (J22.9-xi) against CD269 (BCMA), a plasma membrane receptor expressed nearly exclusively in plasma cells; the antibody shows potent cell killing activity on MM cells *in vitro* and anti-tumor activity *in vivo*. Surface Plasmon Resonance Spectrometry (SPR) measurements gave an exceptionally high affinity of J22.9-xi for BCMA of 50 pM [@bib2]. Although higher affinity antibody:antigen interactions have been achieved by protein engineering/selection techniques [@bib3], the J22.9-xi interaction exceeds the low nanomolar affinity range typical of therapeutic antibodies [@bib4], [@bib5] (see also, for example, Herceptin at 5 nM [@bib6] and Rituximab at 8 nM [@bib7]) by approximately 100-fold.

A protruding loop in the antigen BCMA (the D*x*L loop) with Leu17 at its apex is critical for binding to the native BCMA ligands, B cell Activating Factor of the TNF Family (BAFF) and A PRoliferation Inducing Ligand (APRIL) [@bib8], both of which have a hydrophobic cavity that packs tightly around Leu17. Our 1.89 Å X-ray structure of a J22.9-xi Fab fragment in complex with BCMA shows that J22.9-xi also targets the D*x*L loop ([Fig. 1](#f0005){ref-type="fig"}A). However, the Leu17 binding cavity in J22.9-xi is substantially larger than the Leu17 side chain and provides only limited hydrophobic interactions between Leu17 and the VL of the antibody, primarily with Tyr91; the remainder of the binding cavity is filled with 6 water molecules that pack against the side of Leu17 opposite the Tyr91 interaction ([Fig. 1](#f0005){ref-type="fig"}A, B and C). This high affinity interaction comprises few minor direct contacts between the molecules (4 direct hydrogen bonds and 21 mostly single atom van der Waals contacts) but at least 50 hydrogen bonds involving waters "bridging" interactions between main chain and side chain atoms; 17 of these water molecules are directly in the binding interface ([Table 1](#t0005){ref-type="table"}). Thus, the structure shows how high affinity binding can be achieved with only a small number of direct interactions between the binding partners.

2. Analysis of binding interface {#s0015}
================================

Direct atom to atom contacts between BCMA and the VH and VL of J22.9-xi were identified using the PISA interaction server [@bib9]. Direct and indirect hydrogen bonding interactions involving water were identified and validated (distance and geometry) from the structure using LigPlot [@bib10] and COOT [@bib11].

Appendix A. Supplementary material {#s0025}
==================================

Supplementary material

The authors wish to thank the Helmholtz Gemeinschaft for financial support.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.12.023](http://dx.doi.org/10.1016/j.dib.2015.12.023){#ir0015}.

![Water molecules in the J22.9-xi binding site. **A.** A view of the binding interaction between BCMA (magenta) and the variable domains of the heavy chain (VH, blue) and light chain (VL, yellow). Interface water molecules participating in bridging hydrogen bonding interactions between BCMA and J22.9-xi are depicted as cyan spheres with a radius of 1.4 Å. For clarity only some interface residues (with the corresponding chain color) and some interface waters (with chain numbers directly on the spheres) are labeled. Leu17 in the BCMA *Dx*L loop is shown in space-filling representation. **B.** A view looking down on the binding cavity in J22.9-xi with BCMA removed. The Fab fragment is shown in surface representation with the heavy chain colored blue and the light chain colored yellow. Some of the residues making direct contacts to BCMA are indicated with arrows and darker coloring. **C.** View as in (**B**) with interface waters depicted as cyan spheres and labeled as in (**A**).](gr1){#f0005}

###### 

Water interactions in the J22.9-xi:CD269 complex. The interaction partners are read from left to right across the table, with the corresponding H-bond distances and thermal displacement (B) factors of the indicated water molecules listed (J22.9-xi:H~2~O:CD269). For example, Ser31 from the J22.9-xi light chain participates in a hydrogen bonding interaction with water 409B at a distance of 2.50 Å and water 409B in turn interacts with Thr32 of CD269 at a distance of 2.65 Å. The data in [Table 1](#t0005){ref-type="table"} were generated using the software LigPlot [@bib8] and COOT [@bib11].

Table 1

  **Light Chain (B)**   **H**~**2**~**O\#**   **CD269 (F)**    **Distance (Å)**         **B (Å**^**2**^**)**
  --------------------- --------------------- ---------------- ------------------------ ----------------------
  Ser31 (sc)            409B                  Thr32 (sc, mc)   2.50, 2.65 (sc)          24.33
  2.50, 3.15 (mc)                                                                       
                        409B, 110F            Arg27 (sc)       2.65, 2.60, 2.98         24.33, 23.47
                        409B, 110F            Ser30 (sc)       2.50, 2.65, 2.69         24.33, 23.47
  Ser31 (mc)            458B, 114F            Arg27 (sc)       2.71, 2.75, 2.78         26.48, 28.32
  Asn32 (sc)            439B                  Asp15 (sc)       2.67, 2.88               19.24
                        439B, 114F            Arg27 (sc)       2.67, 2.94, 2.78         19.24, 28.32
                        486B                  Ser16 (sc)       2.80, 3.18               15.45
  Tyr36 (sc)            522B, 336A, 377A      Leu17 (mc)       3.19, 2.90, 2.77, 2.88   14.87, 18.33, 35.33
  Ser50 (sc)            439B                  Asp15 (sc)       3.11, 2.88               19.24
  Ser52 (sc)            110F                  Ser30 (sc)       2.73, 2.69               23.47
                        110F                  Arg27 (sc)       2.73, 2.98               23.47
  Ser52 (sc)            479B, 103F            Ser30 (mc)       2.78, 2.65, 2.94         25.34, 31.49
  Ser29 (sc)            2.78, 2.65, 2.54                                                
                        110F, 409B            Thr32 (sc, mc)   2.73, 2.60, 2.65         23.47, 24.33
  Gly66 (mc)            409B                  Thr32 (sc)       2.86, 2.65               24.33
                        409B, 110F            Arg27 (sc)       2.86, 2.60, 2.98         24.33, 23.47
                        409B, 110F            Ser30 (sc)       2.86, 2.60, 2.69         24.33, 23.47
  Gln89 (sc)            522B, 336A, 377A      Leu17 (mc)       2.92, 2.90, 2.77, 2.88   18.47, 18.33, 35.33
  Tyr91 (mc)            111F                  Ser16 (sc)       2.89, 2.71               32.32
                        111F, 112F            Ser16 (mc)       2.89, 2.79, 2.76         32.32, 23.28
  Tyr94 (sc)            112F                  Ser16 (mc)       3.12, 2.76               23.28
                        112F, 111F            Ser16 (sc)       3.12, 2.79, 2.71         23.28, 32.32
                                                                                        
  **Heavy Chain (A)**   **H**~**2**~**O\#**   **CD269 (F)**    **Distance (Å)**         **B (Å2)**
  Trp33 (mc)            421A, 108F            Leu17 (mc)       2.98, 2.76, 2.62         16.25, 31.34
                        418A                  Leu18 (mc)       2.90, 3.45               19.66
  Ser35 (sc)            421A, 108F            Leu17 (mc)       2.91, 2.76, 2.62         16.25, 31.34
  336A, 377A                                                                            
  2.64, 2.77, 2.88      18.33, 35.33                                                    
  Trp47 (sc)            336A, 377A            Leu17 (mc)       2.96, 2.77, 2.88         18.33, 35.33
  Glu50 (sc)            112F                  Ser16 (mc)       3.21, 2.76               23.28
                        112F, 111F            Ser16 (sc)       3.21, 2.79, 2.71         23.28, 32.32
                        377A                  Leu17 (mc)       2.75, 2.88               35.33
                        377A, 108F            Leu17 (mc)       2.75, 2.48, 2.62         35.33, 31.34
  Leu99 (mc)            108F                  Leu17 (mc)       3.26, 2.62               31.34
  Tyr101 (mc)           105F                  Leu18 (mc)       3.50, 2.57               25.20

(sc=side chain H-bond; mc=main chain H-bond)
